CBD Nutraceuticals Market is estimated to Reach USD 17.9 Billion by 2034, with a 16.40% CAGR and Meeting Growing Wellness Demands - By PMI
February 27, 2024 17:30 ET
|
PMI
Covina, Feb. 27, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the CBD Nutraceuticals Market size was valued at about USD 4.5 Billion in 2024 and expected to grow at CAGR of...
CV Sciences, Inc. Reports Second Quarter 2021 Financial Results
August 12, 2021 16:05 ET
|
CV Sciences, Inc.
SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV Sciences, Inc. to Announce Second Quarter 2021 Results on August 12, 2021
August 05, 2021 08:00 ET
|
CV Sciences, Inc.
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV Sciences, Inc. to Announce Fiscal Year and Fourth Quarter 2020 Results on March 18, 2021
March 10, 2021 07:00 ET
|
CV Sciences, Inc.
SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV Sciences, Inc. Announces Closing of Committed Equity Financing Transaction
December 08, 2020 07:00 ET
|
CV Sciences, Inc.
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV Sciences, Inc. Reports Second Quarter 2020 Financial Results
August 06, 2020 16:05 ET
|
CV Sciences, Inc.
SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV Sciences, Inc. Announces Expansion with the Launch of CV™ Acute and New Immunity Product Line
July 29, 2020 08:00 ET
|
CV Sciences, Inc.
SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today...
CV Sciences, Inc. Announces Plan to Adjourn Annual Meeting of Stockholders to June 16, 2020
May 20, 2020 16:30 ET
|
CV Sciences, Inc.
SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today...
CV Sciences, Inc. Receives Formal Notice of Patent Issuance from USPTO for Proprietary Cannabidiol (CBD) and Nicotine Formulation for Treating Smokeless Tobacco Addiction
May 20, 2020 08:00 ET
|
CV Sciences, Inc.
SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
CV Sciences, Inc. to Announce First Quarter 2019 Results on May 8, 2020
April 30, 2020 16:05 ET
|
CV Sciences, Inc.
SAN DIEGO, April 30, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...